Skip to main content
SpringerLink
Log in

The Relationship of Diabetic Retinopathy and Glaucoma

  • Chapter
  • First Online:
Diabetic Retinopathy

Abstract

Diabetes, diabetic retinopathy, and their various treatments can each influence a patient’s risk of developing not only neovascular glaucoma, but open angle, narrow angle, and secondary glaucoma as well. After reviewing the connections between these types of glaucoma and diabetes, the pathogenesis and management of neovascular glaucoma will be discussed in detail.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.

    Article  CAS  PubMed  Google Scholar 

  2. Wild S, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053.

    Article  PubMed  Google Scholar 

  3. Bonovas S, Peponis V, Filioussi K. Diabetes mellitus as a risk factor for primary open-angle glaucoma: a meta-analysis. Diabetes Med. 2004;21:609–614.

    Article  CAS  Google Scholar 

  4. Chopra V, Varma R, Francis BA et al. Type 2 diabetes mellitus and the risk of open-angle glaucoma. The Los Angeles Latino Eye Study. Ophthalmology. 2008;115:227–232.

    Article  PubMed  Google Scholar 

  5. Memarzadeh F, Ying-Lai M, Azen SP, Varma R, on behalf of the Los Angeles Latino Eye Study Group. Associations with intraocular pressure in Latinos: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2008;146:69–76.

    Article  PubMed  Google Scholar 

  6. Nakamura M, Kanamori A, Negi A. Diabetes mellitus as a risk factor for glaucomatous optic neuropathy. Ophthalmologica. 2005;219:1–10.

    Article  PubMed  Google Scholar 

  7. Krueger RR, Ramos-Esteban JC. How might corneal elasticity help us understand diabetes and intraocular pressure? J Refract Surg. 2007;23:85–88.

    PubMed  Google Scholar 

  8. The Advanced Glaucoma Intervention Study (AGIS):12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol. 2002;134:499–512.

    Google Scholar 

  9. Armstrong JR, Daily RK, Dobson HL, Girard LJ. The incidence of glaucoma in diabetes mellitus. A comparison with the incidence of glaucoma in the general population. Am J Ophthalmol. 1960;50:55–63.

    CAS  PubMed  Google Scholar 

  10. Becker B. Diabetes mellitus and primary open-angle glaucoma. The XXVII Edward Jackson Memorial Lecture. Am J Ophthalmol. 1971;1:1–16.

    Google Scholar 

  11. De Voogd S, Ikram MK, Wolfs RC, et al. Is diabetes mellitus a risk factor for open-angle glaucoma? The Rotterdam Study. Ophthalmology. 2006;113:1827–1831.

    Article  PubMed  Google Scholar 

  12. Klein BE, Klein R, Jensen SC. Open-angle glaucoma and older-onset diabetes. The Beaver Dam Eye Study. Ophthalmology. 1994;101:1173–1177.

    CAS  PubMed  Google Scholar 

  13. Klein BE, Klein R, Moss SE. Intraocular pressure in diabetic persons. Ophthalmology. 1984;91:1356–1360.

    CAS  PubMed  Google Scholar 

  14. Klein BE, Klein R, Moss SE. Incidence of self reported glaucoma in people with diabetes mellitus. Br J Ophthalmol. 1997;81:743–747.

    Article  CAS  PubMed  Google Scholar 

  15. Mitchell P, Smith W, Chey T, et al. Open-angle glaucoma and diabetes: the Blue Mountains Eye Study. Australia. Ophthalmology. 1997;104:712–718.

    CAS  PubMed  Google Scholar 

  16. Nielsen NV. The prevalence of glaucoma and ocular hypertension in type 1 and 2 diabetes mellitus. An epidemiological study of diabetes mellitus on the island of Falster, Denmark. Acta Ophthalmol. 1983;61:662–672.

    CAS  Google Scholar 

  17. Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol. 1983;118:166–191.

    CAS  PubMed  Google Scholar 

  18. Wu SY, Leske MC. Associations with intraocular pressure in the Barbados Eye Study. Arch Ophthalmol. 1997;115:1572–1576.

    CAS  PubMed  Google Scholar 

  19. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open-angle glaucoma: the Egna–Neumarkt Study. Ophthalmology. 2000;107:1287–1293.

    Article  CAS  PubMed  Google Scholar 

  20. Hennis A, Wu SY, Nemesure B, Leske MC. Hypertension, diabetes, and longitudinal changes in intraocular pressure. Ophthalmology. 2003;110:908–914.

    Article  PubMed  Google Scholar 

  21. Dielemans I, de Jong PT, Stolk R, Vingerling JR, Grobbee DE, Hofman A. Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population: the Rotterdam Study. Ophthalmology. 1996;103:1271–1275.

    CAS  PubMed  Google Scholar 

  22. Bankes JL. Ocular tension and diabetes mellitus. Br J Ophthalmol. 1967;51:557–561.

    Article  CAS  PubMed  Google Scholar 

  23. Grødum K, Heijl A, Bengtsson B. Optic disc hemorrhages and generalized vascular disease. J Glaucoma. 2002;11:226–230.

    Article  PubMed  Google Scholar 

  24. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol. 1977;106:33–41.

    CAS  PubMed  Google Scholar 

  25. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975. Surv Ophthalmol. 1980;24:335–610.

    Article  CAS  PubMed  Google Scholar 

  26. Leske MC, Connell AM, Wu SY, et al. Risk factors for open angle glaucoma. The Barbados Eye Study. Arch Ophthalmol. 1995;113:918–924.

    CAS  PubMed  Google Scholar 

  27. Tielsch JM, Katz J, Quigley HA, et al. Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Survey. Ophthalmology. 1995;102:48–53.

    CAS  PubMed  Google Scholar 

  28. Wilson MR, Hertzmark E, Walker AM, et al. A case–control study of risk factors in open angle glaucoma. Arch Ophthalmol. 1987;105:1066–1071.

    CAS  PubMed  Google Scholar 

  29. Ellis JD, Morris AD, MacEwen CJ. Should diabetic patients be screened for glaucoma? DARTS/MEMO Collaboration. Br J Ophthalmol. 1999;83:369–372.

    Article  CAS  PubMed  Google Scholar 

  30. Pache M and Flammer J. A sick eye in a sick body? Systemic findings in patients with primary open-angle glaucoma. Surv Ophthalmol. 2006;51:179–212.

    Article  Google Scholar 

  31. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Kass MA, for the Ocular Hypertension Treatment Study Group. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714–720.

    PubMed  Google Scholar 

  32. Blake DR, Nathan DM. Acute angle closure glaucoma following rapid correction of hyperglycemia. Diabetes Care. 2003;26:3197–3198.

    Article  PubMed  Google Scholar 

  33. Sorokanich S, Wand M, Nix HR. Angle closure glaucoma and acute hyperglycemia. Arch Ophthalmol. 1986;104:1434.

    CAS  PubMed  Google Scholar 

  34. Smith JP. Angle closure glaucoma and acute hyperglycemia (Letter). Arch Ophthalmol. 1987;105:454–455.

    CAS  PubMed  Google Scholar 

  35. Clark CV. Diabetes mellitus in primary glaucomas. Ann Acad Med Singapore. 1989;18:190–194.

    CAS  PubMed  Google Scholar 

  36. Saw SM, Wong TY, Ting S, Foong AW, Foster PJ. The relationship between anterior chamber depth and the presence of diabetes in the Tanjong Pagar Survey. Am J Ophthalmol. 2007;144:325–326.

    Article  PubMed  Google Scholar 

  37. Wiemer NGM, Dubbelman M, Kostense PJ, Ringens PF, Polak BCP. The influence of diabetes mellitus type 1 and 2 on the thickness, shape, and equivalent refractive index of the human crystalline lens. Ophthalmology. 2008;115:1679–1686.

    Article  PubMed  Google Scholar 

  38. Wiemer NGM, Dubbelman M, Hermans EA, Ringens PF, Polak BCP. Changes in the internal structure of the human crystalline lens with diabetes mellitus type 1 and type 2. Ophthalmology. 2008;115:2017–2023.

    Article  PubMed  Google Scholar 

  39. Jones R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163–167.

    PubMed  Google Scholar 

  40. Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007;52:503–522.

    Article  CAS  PubMed  Google Scholar 

  41. Kramar M, Vu L, Whitson JT, He YG. The effect of intravitreal triamcinolone on intraocular pressure. Curr Med Res Opin. 2007;23:1253–1258.

    Article  CAS  PubMed  Google Scholar 

  42. Batioglu F, Ozmert E, Parmak N, Celik S. Two year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema. Int Ophthalmol. 2007;27:299–306.

    Article  PubMed  Google Scholar 

  43. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina. 2008;28:573–580.

    Article  PubMed  Google Scholar 

  44. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two year results of a double masked, placebo controlled, randomized clinical trial. Ophthalmology. 2006;113:1533–1538.

    Article  PubMed  Google Scholar 

  45. Lau LI, Chen KC, Lee FL, Chen SJ, Ko YC, Liu CJL, Hsu WM. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection in a Chinese population. Am J Ophthalmol. 2008;146:573–578.

    Article  CAS  PubMed  Google Scholar 

  46. Cunningham MA, Edelman JF, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53:139–149.

    Article  PubMed  Google Scholar 

  47. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant. Arch Ophthalmol. 2008;126:1191–1201.

    Article  PubMed  Google Scholar 

  48. Ricci F, Missiroli F, Parravano M. Argon laser trabeculoplasty in triamcinolone acetonide induced ocular hypertension refractory to maximal medical treatment. Eur J Ophthalmol. 2006;16:756–757.

    CAS  PubMed  Google Scholar 

  49. Viola F, Morescalchi F, Staurenghi G. Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. Arch Ophthalmol. 2006;124:133–134.

    Article  PubMed  Google Scholar 

  50. Rubin B, Taglienti A, Rothman RF, Marcus CH, Serle JB. The effect of selective laser trabeculoplasty on intraocular pressure in patients with intravitreal steroid-induced elevated intraocular pressure. J Glaucoma. 2008;17:287–292.

    Article  PubMed  Google Scholar 

  51. Realini T. Selective laser trabeculoplasty: a review. J Glaucoma. 2008;17:497–502.

    Article  PubMed  Google Scholar 

  52. Robin AL, Sjaarda R, Suan EP. A novel long-lasting therapy for glaucoma caused by intravitreal triamcinolone acetonide: anterior juxtascleral depot of anecortave acetate. Presented at Annual Meeting of the American Glaucoma Society, Charleston, SC, March 2006.

    Google Scholar 

  53. Robin AL, et al. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open angle glaucoma: a pilot investigation. Am J Ophthalmol. 2009;147:45–50.

    Article  CAS  PubMed  Google Scholar 

  54. Katz GJ, et al. A study of anecortave acetate (7.5 and 15 mg) vs vehicle in patients with open angle glaucoma. Presented at American Academy of Ophthalmology meeting, November 2008.

    Google Scholar 

  55. Eid TM, Radwan A, el-Manawy W, el-Hawary I. Outcome of intravitreal bevacizumab (Avastin) followed by aqueous shunting tube surgery for management of intractable neovascular glaucoma. Poster at American Academy of Ophthalmology November 2008.

    Google Scholar 

  56. Kuang TM, Liu CJ, Chou CK, Hsu WM. Clinical experience in the management of neovascular glaucoma. J Chin Med Assoc. 2004;67:131–135.

    PubMed  Google Scholar 

  57. Nabili S, Kirkness CM. Trans-scleral diode laser cyclophoto-coagulation in the treatment of diabetic neovascular glaucoma. Eye. 2004;18:352–256.

    Google Scholar 

  58. Sothornwit N. Intravitreal bevacizumab for Ahmed glaucoma valve implantation in neovascular glaucoma: a case report. J Med Assoc Thai. 2008;91(Suppl 1):S162–S165.

    Google Scholar 

  59. Wand M, Dueker DK, Aiello LM, Grant WM. Effects of panretinal photocoagulation on rubeosis iridis, angle neovascularization, and neovascular glaucoma. Am J Ophthalmol. 1978;86:332–339.

    CAS  PubMed  Google Scholar 

  60. Ringvold A, Davanger M. Iris neovascularization in eyes with pseudoexfoliation syndrome. Br J Ophthalmol. 1981;65:138–141.

    Article  CAS  PubMed  Google Scholar 

  61. Shimizu K, Kobayashi K, Muraoka K. Midperipheral fundus involvement in diabetic retinopathy. Ophthalmology. 1981;88:601–612.

    CAS  PubMed  Google Scholar 

  62. Hamanaka T, Akabane N, Yajima T, et al. Retinal ischemia and angle neovascularization in proliferative diabetic retinopathy. Am J Ophthalmol. 2001;132:648–658.

    Article  CAS  PubMed  Google Scholar 

  63. Terasaki H, Miyake Y, Mori M, et al. Fluorescein angiography of extreme peripheral retina and rubeosis iridis in proliferative diabetic retinopathy. Retina. 1999;19:302–308.

    Article  CAS  PubMed  Google Scholar 

  64. Steel DHW, Habib MS, Park S, et al. Entry site neovascularization and vitreous cavity hemorrhage after diabetic vitrectomy the predictive value of inner sclerostomy site ultrasonography. Ophthalmology. 2008;115:525–532.

    Article  CAS  PubMed  Google Scholar 

  65. Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol. 2002;133:373–385.

    Article  CAS  PubMed  Google Scholar 

  66. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and III, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic patients. J Clin Invest. 1993;92:2620–2625.

    Article  CAS  PubMed  Google Scholar 

  67. John T, Sassani JW, Eagle RC. The myofibroblastic component of rubeosis iridis. Ophthalmology. 1983;90:721–728.

    CAS  PubMed  Google Scholar 

  68. Rice TA, Michels RG, Maguire MG, Rice EF. The effect of lensectomy on the incidence of iris neovascularization and neovascular glaucoma after vitrectomy for diabetic retinopathy. Am J Ophthalmol. 1983;95:1–11.

    CAS  PubMed  Google Scholar 

  69. Tolentino MJ, Miller JW, Gragoudis ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996;114:964–970.

    CAS  PubMed  Google Scholar 

  70. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66–71.

    CAS  PubMed  Google Scholar 

  71. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment. Retina, J Retin Vitreous Dis. 2006;26:352–356.

    Google Scholar 

  72. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26:354–356.

    Article  PubMed  Google Scholar 

  73. Tripathi RC, Li J, Tripathi BJ, et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232–237.

    Article  CAS  PubMed  Google Scholar 

  74. Gartner S, Henkind P. Neovascularization of the iris (rubeosis iridis). Surv Ophthalmol. 1978;22:291–312.

    Article  CAS  PubMed  Google Scholar 

  75. Anderson DM, Morin JD, Hunter WS. Rubeosis iridis. Can J Ophthalmol. 1971;6:183–188.

    CAS  PubMed  Google Scholar 

  76. Schulze RR. Rubeosis iridis. Am J Ophthalmol. 1967;63:487–495.

    CAS  PubMed  Google Scholar 

  77. Weiter J, Zuckerman R. The influence of the photoreceptor–RPE complex on the inner retina. Ophthalmology. 1980;87:1133–1139.

    CAS  PubMed  Google Scholar 

  78. Aiello LP, Arrigg PG, Keyt BA, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Eng J Med. 1994;331:1480–1487.

    Article  CAS  PubMed  Google Scholar 

  79. Ohrt V. Rubeosis iridis diabetica. Acta Ophthalmol. 1958;36:556–558.

    CAS  Google Scholar 

  80. Ohnishi Y, Ishibashi T, Sagawa T. Fluorescein gonioangiography in diabetic neovascularization. Graefe's Arch Clin Exp Ophthalmol. 1994;232:199–204.

    Article  CAS  Google Scholar 

  81. Helbig H, Kellner U, Bornfeld N, Foerster MH. Rubeosis iridis after vitrectomy for diabetic retinopathy. Graefe's Arch Clin Exp Ophthalmol. 1998;236:730–733.

    Article  CAS  Google Scholar 

  82. Michels R. Vitrectomy for complications of diabetic retinopathy. Arch Ophthalmol. 1978;96:237–246.

    CAS  PubMed  Google Scholar 

  83. Bandello F, Brancato R, Lattanzio R, et al. Relation between iridopathy and retinopathy in diabetes. Br J Ophthalmol. 1994;78:542–545.

    Article  CAS  PubMed  Google Scholar 

  84. Tasman W, Magargal LE, Augsburger JJ. Effects of argon laser photocoagulation on rubeosis iridis and angle neovascularization. Ophthalmology. 1980;87:400–402.

    CAS  PubMed  Google Scholar 

  85. Diabetic Retinopathy Study Research Group. Diabetic retinopathy study, report number 6: design, methods, and baseline results. Invest Ophthalmol Vis Sci. 1981;21:149–209.

    Google Scholar 

  86. Ohrt V. The frequency of rubeosis iridis in diabetic patients. Ophthalmologica. 1971;49:301–307.

    CAS  Google Scholar 

  87. Murphy RP, Egbert PR. Regression of iris neovascularization following panretinal photocoagulation. Arch Ophthalmol. 1979;97:700–702.

    CAS  PubMed  Google Scholar 

  88. Teich SA, Walsh JB. A grading system for iris neovascularization-prognostic implications for treatment. Ophthalmology. 1981;88:1102–1106.

    CAS  PubMed  Google Scholar 

  89. Aiello LM, Wand M, Liang G. Neovascular glaucoma and vitreous hemorrhage following cataract surgery in patients with diabetes mellitus. Ophthalmology. 1983;90:814–820.

    CAS  PubMed  Google Scholar 

  90. Browning DJ. Risk of missing angle neovascularization by omitting screening gonioscopy in patients with diabetes mellitus. Am J Ophthalmol. 1991;112:212.

    CAS  PubMed  Google Scholar 

  91. Browning DJ, Scott AQ, Peterson CB, et al. The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion. Ophthalmology. 1998;105:776–784.

    Article  CAS  PubMed  Google Scholar 

  92. Pe'er J, Neufeld M, Baras M, et al. Rubeosis in retinoblastoma – histologic findings and the possible role of vascular endothelial growth factor in its induction. Ophthalmology. 1997;104:1251–1258.

    PubMed  Google Scholar 

  93. Henkind P. Ocular neovascularization. The Krill Memorial Lecture. Am J Ophthalmol. 1978;85:287–301.

    CAS  PubMed  Google Scholar 

  94. Ehrenberg M, McCuen BW, Schindler RH, Machemer R. Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids. Ophthalmology. 1984;91:321–325.

    CAS  PubMed  Google Scholar 

  95. Scuderi JJ, Blumenkranz MS, Blankenship G. Regression of diabetic rubeosis iridis following successful surgical reattachment of the retina by vitrectomy. Retina. 1982;2:193–196.

    Article  CAS  PubMed  Google Scholar 

  96. Tolentino FI, Cajita VN, Gancayco T, Skates S. Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy. Ophthalmology. 1989;96:1495–1500.

    CAS  PubMed  Google Scholar 

  97. Lewis H, Abrams GW, Williams GA. Anterior hyaloidal fibrovascular proliferation after diabetic vitrectomy. Am J Ophthalmol. 1987;104:607–613.

    CAS  PubMed  Google Scholar 

  98. Lewis H, Abrams GW, Foos RY. Clinicopathologic findings in anterior hyaloidal fibrovascular proliferation after diabetic vitrectomy. Am J Ophthalmol. 1987;104:614–618.

    CAS  PubMed  Google Scholar 

  99. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything alright? JAMA. 1983;259:1743–1745.

    Article  Google Scholar 

  100. Eypasch E, Lefering R, Kum CK. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ. 1995;311:619–620.

    CAS  PubMed  Google Scholar 

  101. Blinder KJ, Friedman SM, Mames RN. Diabetic iris neovascularization. Am J Ophthalmol. 1998;120:393–395.

    Google Scholar 

  102. Brancato R, Bandello F, Lattanzio R. Iris fluorescein angiography in clinical practice. Surv Ophthalmol. 1997;42:41–70.

    Article  CAS  PubMed  Google Scholar 

  103. Mandelbaum S, Chew EY, Christman LM, et al. Comprehensive adult medical eye evaluation. 2008. American Academy of Ophthalmology.

    Google Scholar 

  104. Coleman SL, Green WR, Patz A. Vascular tufts of the pupillary margin of the iris. Am J Ophthalmol. 1977;83:881–883.

    CAS  PubMed  Google Scholar 

  105. Dahlmann AH, Benson MT. Spontaneous hyphema secondary to iris vascular tufts. Arch Ophthalmol. 2001;119:1728.

    CAS  PubMed  Google Scholar 

  106. Davies N. Letter. Eye. 2001;15:688–691.

    CAS  PubMed  Google Scholar 

  107. Bandello F, Brancato R, Lattanzio R, et al. Biomicroscopy versus fluorescein angiography of the iris in the detection of diabetic iridopathy. Graefes Arch Clin Exp Ophthalmol. 1993;231:444–448.

    Article  CAS  PubMed  Google Scholar 

  108. Sanborn GE, Symes DJ, Magaragal LE. Fundus-iris fluorescein angiography: evaluation of its use in the diagnosis of rubeosis iridis. Ann Ophthalmol. 1986;18:52–58.

    CAS  PubMed  Google Scholar 

  109. Jensen VA, Lundbaek K. Fluorescence angiography of the iris in recent and long-term diabetics. Acta Ophthalmol. 1968;46:584–585.

    CAS  Google Scholar 

  110. Kottow MH. Iris neovascular tufts. Arch Ophthalmol. 1980;98:2084.

    CAS  PubMed  Google Scholar 

  111. Vannas A. Fluorescein angiography of the vessels of the iris. Acta Ophthalmol. 1969;105:1–75.

    CAS  Google Scholar 

  112. Parodi MB, Bondel E, Russo D, Ravalico G. Iris indocyanine green video angiography in diabetic iridopathy. Br J Ophthalmol. 1996;80:416–419.

    Article  CAS  PubMed  Google Scholar 

  113. Tauber J, Lahav M, Erzurum SA. New clinical classification for iris neovascularization. Ophthalmology. 1987;94:542–544.

    CAS  PubMed  Google Scholar 

  114. Nomura T, Furukawa H, Kurinoto S. Development and classification of neovascular glaucoma in diabetic eye disease: histopathological study. Acta Ophthalmol Soc Jpn. 1976;86:166–175.

    Google Scholar 

  115. Kubota T, Tawara A, Hata T, et al. Neovascular tissue in the intertrabecular spaces in eyes with neovascular glaucoma. Br J Ophthalmol. 1996;80:750–754.

    Article  CAS  PubMed  Google Scholar 

  116. Weiss DI, Gold D. Neofibrovascularization of iris and anterior chamber angle: a clinical classification. Ann Ophthalmol. 1978;10:488–491.

    CAS  PubMed  Google Scholar 

  117. Little HL, Rosenthal AR, Dellaporta A, Jacobson DR. The effect of panretinal photocoagulation on rubeosis iridis and neovascular glaucoma. Am J Ophthalmol. 1976;81:804–809.

    CAS  PubMed  Google Scholar 

  118. Beasley H. Rubeosis iridis in aphakic diabetics. JAMA. 1970;213:128.

    Article  CAS  PubMed  Google Scholar 

  119. Schiff WM, Barile GR, Hwang JC et al. Diabetic vitrectomy: influence of lens status upon anatomic and visual outcomes. Ophthalmology. 2007;114:544–550.

    Article  PubMed  Google Scholar 

  120. Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007;114:710–715.

    Article  PubMed  Google Scholar 

  121. Yeh PT, Yang CM, Yang CH, Huang JS. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage. Ophthalmology. 2005;112:2095–2102.

    Article  PubMed  Google Scholar 

  122. Azzolini C, Brancato R, Camesasca FI, August 1993 (Vol.100 I8PP). Influence of silicone oil on iris microangiopathy in diabetic vitrectomized eyes. Ophthalmology. 1993;100:1152–1158.

    Google Scholar 

  123. Laatikainen L. Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and neovascular glaucoma. Br J Ophthalmol. 1977;61:278–284.

    Google Scholar 

  124. Vernon SA, Cheng H. Panretinal cryotherapy in neovascular disease. Br J Ophthalmol. 1988;72:401–405.

    Article  CAS  PubMed  Google Scholar 

  125. Pauleikhoff D, Gerke E. Photocoagulation in diabetic rubeosis iridis and neovascular glaucoma. Klin Monatsbl Augenheil. 1987;190:11–16.

    Article  CAS  Google Scholar 

  126. Striga M, Ivanisevic M. Comparison between efficacy of full- and mild-scatter (panretinal) photocoagulation on the course of diabetic rubeosis iridis. Ophthalmologica. 1993;207:144–147.

    Article  CAS  PubMed  Google Scholar 

  127. Parodi MB, Iacono P. Photodynamic therapy with verteporfin for anterior segment neovascularizations in neovascular glaucoma. Am J Ophthalmol. 2004;138:157–158.

    Article  CAS  PubMed  Google Scholar 

  128. Spiteri Cornish K, Ramamurthi S, Saidkasimova S, Ramaesh K. Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye. 2008;23:979–981.

    Article  PubMed  Google Scholar 

  129. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695–1705.

    Article  PubMed  Google Scholar 

  130. Grover S, Gupta SK, Sharma RK, Brar VS, Chalam KV. Intracameral bevacizumab effectively reduces aqueous VEGF levels in neovascular glaucoma. Br J Ophthalmol. 2009;93:1273–1274.

    Article  Google Scholar 

  131. Chalam KV, Gupta SK, Grover S, Brar VS, Agarwal S. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol. 2008;18:255–262.

    CAS  PubMed  Google Scholar 

  132. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU, Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006;142:158–160.

    Article  CAS  PubMed  Google Scholar 

  133. Miki A, Oshima Y, Otori Y, et al. Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma. Br J Ophthalmol. 2008;92:1431–1433.

    Article  CAS  PubMed  Google Scholar 

  134. May DR, Bergstrom TJ, Parmet AJ, Schwartz JG. Treatment of neovascular glaucoma with transscleral panretinal cryotherapy. Ophthalmology. 1980;87:1106–1111.

    CAS  PubMed  Google Scholar 

  135. Flaxel CJ, Larkin GB, Broadway DB, et al. Peripheral transscleral retinal diode laser for rubeosis iridis. Retina. 1997;17:421–429.

    CAS  PubMed  Google Scholar 

  136. Hilton GF. Panretinal cryotherapy for diabetic rubeosis. Arch Ophthalmol. 1979;97:776.

    CAS  PubMed  Google Scholar 

  137. Allen RC, Bellows AR, Hutchinson BT, Murphy SD. Filtration surgery in the treatment of neovascular glaucoma. Ophthalmology. 1982;89:1181–1187.

    CAS  PubMed  Google Scholar 

  138. Skuta GL, Parrish RK II. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987;32:149–170.

    Article  CAS  PubMed  Google Scholar 

  139. Miller JW, StinsonWG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology. 2008;100:9–14.

    Google Scholar 

  140. Genaidy M, Kazi A, Peyman G, et al. Effect of squalamine on iris neovascularization in monkeys. Retina. 2002;22:772–778.

    Article  PubMed  Google Scholar 

  141. Sir Duke-Elder S., Jay B. eds. Haemorrhagic glaucoma. In: System of Ophthalmology. Vol. 9. London: Henry Kimpton;1969:667.

    Google Scholar 

  142. Sivak-Callcott JS, O’Day DM, Gass JDM, Tsai JC. Evidence based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108:1767–1778.

    Article  CAS  PubMed  Google Scholar 

  143. Ehlers JP, Shah CP, Fenton GL, Hoskins EN, Shelsta HN. The Wills Eye Manual: office and Emergency Room Diagnosis and Treatment of Eye Disease. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:214–217.

    Google Scholar 

  144. Silva Paula J, Jorge R, Alves Costa R, Rodrigues Mde L, Scott IU. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand. 2006;84:556–557.

    Article  PubMed  Google Scholar 

  145. Oshima Y, Sakgauchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:155–158.

    Article  CAS  PubMed  Google Scholar 

  146. Beutel J, Peters S, Luke M, Aisenbrey S, Szurman P, Spitzer MS, Yoeruek E, The Bevacizumab Study Group, Grisanti S. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol. Sept 20, 2008 (E-pub).

    Google Scholar 

  147. Jiang Y, Liang X, Li X, Tao Y, Wang K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol. 2008 Sep 18 (E-pub)

    Google Scholar 

  148. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina. 2008;28:696–702.

    Article  PubMed  Google Scholar 

  149. Gheith ME, Siam GA, de Barros DS, Garg SJ, Moster MR. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther. 2007;23:487–491.

    Article  CAS  PubMed  Google Scholar 

  150. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra G-M. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142:1054–1056.

    Article  CAS  PubMed  Google Scholar 

  151. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2007;35:494–496.

    Article  Google Scholar 

  152. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, Otori Y, Kamei M, Kusada S, Tano Y. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115:1571–1580.

    Article  PubMed  Google Scholar 

  153. Martinez-Carpio PA, Bonafonte-Marquez E, Heredia-Garcia CD, Bonafonte-Rovo S. Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systemic review. Arch Soc Esp Oftalmol. 2008;83:579–588.

    Article  CAS  PubMed  Google Scholar 

  154. Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977–982.

    Article  PubMed  Google Scholar 

  155. Sharma, RK, Chalam, KV, et al. Evaluation of cytotoxic effects of bevacizumab on human corneal endothelial cells. Cornea. 2009;28:328–333.

    Article  PubMed  Google Scholar 

  156. Netland PA. The Management of Neovascular Glaucoma in 2008. Presentation at the annual meeting of the American Academy of Ophthalmology, Atlanta, GA. November 10, 2008.

    Google Scholar 

  157. Al Obeidan SA, Osman EA, Al-Amro SA, Kangave D, Abu El-Asrar AM. Full preoperative panretinal photocoagulation improves the outcome of trabeculectomy with mitomycin C for neovascular glaucoma. Eur J Ophthalmol. 2008;18:758–764.

    CAS  PubMed  Google Scholar 

  158. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther. 2008;25:438–443.

    Article  CAS  PubMed  Google Scholar 

  159. Pappas GD, Panagiotoglou T, Kounali VD, Koukoulasis MG, Fanouriakis CD. Intracameral bevacizumab and augmented trabeculectomy with mitomycin C for the treatment of neovascular glaucoma. Poster at American Academy of Ophthalmology November 2008.

    Google Scholar 

  160. Grewal DS, Jain R, Kumar H, Grewal SPS. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy. Ophthalmology. 2008;115:2141–2145.

    Article  PubMed  Google Scholar 

  161. Welsandt GR, Mietz H, Becker M, et al. Effect of bevacizumab on 3T3 fibroblasts in vitro: possible role in wound healing modulation. Invest Ophthalmol Vis Sci 48:E-abstract 836, 2007.

    Google Scholar 

  162. Icchpujani P, Ramasubramanian A, Kaushik S, Pandav SS. Bevacizumab in glaucoma: a review; Can J Ophthalmol. 2007;42:812–815.

    Article  Google Scholar 

  163. Kapetansky F, et al. Subconjunctival injection(s) of bevacizumab for failing filtering blebs. Poster at American Academy of Ophthalmology November 2008.

    Google Scholar 

  164. Wang J, Harasymowycz PJ. Subconjunctival bevacizumab injection for glaucoma filtering surgery: a case series. Poster at American Academy of Ophthalmology November 2008.

    Google Scholar 

  165. Yalvac IS, Eksioglu U, Satana B, Duman S. Long term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma. Eye. 2007;21:65–70.

    Article  CAS  PubMed  Google Scholar 

  166. Lloyd MA, Sedlak T, Heuer DK, et al. Clinical experience with the single-plate Molteno implant in complicated glaucomas. Ophthalmology. 1992;99:679–687.

    CAS  PubMed  Google Scholar 

  167. Every SG, Molteno AC, Bevin TH, Herbison P. Long term results of Molteno implant insertion in cases of neovascular glaucoma. Arch Ophthalmol. 2006;124:355–360.

    Article  PubMed  Google Scholar 

  168. Luttrul JK, Avery RL. Pars plana implant and vitrectomy for treatment of neovascular glaucoma. Retina. 1995;15:379–387.

    Article  Google Scholar 

  169. Faghihi H, Hajizadeh F, Hahammadi SF, Kadkhoda A, Peyman GA, Riazi-Esfahani M. Pars plana Ahmed valve implant and vitrectomy in the management of neovascular glaucoma. Opthalmic Surg Lasers Imaging. 2007;38:292–300.

    Google Scholar 

  170. Smith MF, Doyle JW, Fanous MM. Modified aqueous drainage implants in the treatment of complicated glaucomas in eyes with pre-existing episcleral bands. Ophthalmology. 1998;105:2237–2242.

    Article  CAS  PubMed  Google Scholar 

  171. Schocket SS. The ‘taco’ tube shunt. In: Chen TC ed. Surgical Techniques in Ophthalmology: Glaucoma Surgery. Philadelphia: Saunders Elsevier; 2008:143–152.

    Google Scholar 

  172. Roth SM, Brown GC. The diagnosis and management of rubeosis iridis. Clin Signs Ophthalmol. 1989;10:1–15.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Charlotte Eye Ear Nose & Throat Associates, Charlotte, NC, 28210, USA

    David J. Browning MD, PhD & Michael H. Rotberg MD

Authors
  1. David J. Browning MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael H. Rotberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David J. Browning MD, PhD .

Editor information

Editors and Affiliations

  1. Throat Associates, Charlotte Eye Ear Nose &, Fairview Road 6035, Charlotte, 28210, USA

    David J. Browning

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Browning, D.J., Rotberg, M.H. (2010). The Relationship of Diabetic Retinopathy and Glaucoma. In: Browning, D. (eds) Diabetic Retinopathy. Springer, New York, NY. https://doi.org/10.1007/978-0-387-85900-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-85900-2_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-85899-9

  • Online ISBN: 978-0-387-85900-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation